Evidence map›Paper›PMID 25237596›Full record

ArticlePeerJ2014

Effects of low and high dose intraarticular tiludronate on synovial fluid and clinical variables in healthy horses-a preliminary investigation.

Katja F Duesterdieck-Zellmer, Lindsey Moneta, Jesse F Ott, Maureen K Larson, Elena M Gorman, Barbara Hunter, Christiane V Löhr, Mark E Payton, Jeffrey T Morré, Claudia S Maier

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Katja F Duesterdieck-ZellmerDepartment of Clinical Sciences, College of Veterinary Medicine, Oregon State University , Corvallis, OR , USA.
Lindsey MonetaCollege of Veterinary Medicine, Oregon State University , Corvallis, OR , USA.
Jesse F OttDepartment of Clinical Sciences, College of Veterinary Medicine, Oregon State University , Corvallis, OR , USA.
Maureen K LarsonDepartment of Clinical Sciences, College of Veterinary Medicine, Oregon State University , Corvallis, OR , USA.
Elena M GormanDepartment of Biomedical Sciences, College of Veterinary Medicine, Oregon State University , Corvallis, OR , USA.
Barbara HunterDepartment of Clinical Sciences, College of Veterinary Medicine, Oregon State University , Corvallis, OR , USA.
Christiane V LöhrDepartment of Biomedical Sciences, College of Veterinary Medicine, Oregon State University , Corvallis, OR , USA.
Mark E PaytonDepartment of Statistics, Oklahoma State University , Stillwater, OK , USA.
Jeffrey T MorréDepartment of Chemistry, Oregon State University , Corvallis, OR , USA.
Claudia S MaierDepartment of Chemistry, Oregon State University , Corvallis, OR , USA.
Oregon State University · USOklahoma State University · US

Funding

Reducing Susceptibility to Environmental Stress Throughout the Life SpanP30ES000210 · NIEHS · OREGON STATE UNIVERSITY · PI BECKMAN, JOSEPH S · 1985 to 2015
$21.4M
NIEHS NIH HHS P30 ES000210
6 · The paper itself

Abstract

To determine effects of intraarticularly administered tiludronate on articular cartilage in vivo, eight healthy horses were injected once with tiludronate (low dose tiludronate [LDT] 0.017 mg, n = 4; high dose tiludronate [HDT] 50 mg, n = 4) into one middle carpal joint and with saline into the contralateral joint. Arthrocentesis of both middle carpal joints was performed pre-treatment, and 10 min, 24 h, 48 h, 7 and 14 days after treatment. Synovial nucleated cell counts and total solids, tiludronate, sulfated glycosaminoglycan (sGAG), chondroitin sulfate 846 epitope (CS-846, a measure of aggrecan synthesis), and collagen type II cleavage neoepitope (C2C) concentrations were determined. Histologic analysis of joint tissues and sGAG quantitation in cartilage was performed at 14 days in HDT horses. Data were analyzed by repeated measures non-parametric ANOVA and Wilcoxon signed-rank test. High dose tiludronate administration produced synovial fluid tiludronate concentrations of 2,677,500 ng/mL, exceeding concentrations that were safe for cartilage in vitro, and LDT administration produced synovial fluid concentrations of 1,353 ng/mL, remaining below concentrations considered potentially detrimental to cartilage. With HDT, synovial fluid total solids concentration was higher at 24 h and 7 days and sGAG concentration was higher at 48 h, compared to control joints. Synovial fluid CS-846 concentration was increased over pre-treatment values in HDT control but not in HDT treated joints at 24 and 48 h. All joints (HDT and LDT control and treated) showed a temporary decrease in synovial fluid C2C concentration, compared to pre-treatment values. Histologic features of articular cartilage and synovial membrane did not differ between HDT treated and control joints. High dose tiludronate treatment caused a transient increase in synovial total solids and temporarily increased proteoglycan degradation in cartilage. Although clinical significance of these changes are questionable, as they did not result in articular cartilage damage, further investigation of the safety of intraarticular HDT in a larger number of horses is warranted.

Indexed as

BisphosphonateCartilageGlycosaminoglycansHorseJoint injectionTiludronate

Identifiers

PMID25237596
PMCPMC4157236
OpenAlexW2165753525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.